- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04450134
Histamine H1/H2 Receptors and Training Adaptations
July 29, 2021 updated by: Wim Derave
Role of Histamine H1/H2 Receptors in the Health- and Performance-promoting Adaptations to High-intensity Interval Training
Exercise training is beneficial for both health and performance.
Histamine has been shown to be involved in the acute exercise response.
The current study addresses the role of histamine H1/H2 receptor signaling in the chronic training-induced adaptations.
Results from this study will yield more insights into the molecular mechanisms of adaptations to exercise training.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
20
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Oost-Vlaanderen
-
Gent, Oost-Vlaanderen, Belgium, 9000
- Department of Movement and Sports Sciences, Ghent University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 50 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Sedentary or low levels of physical activity
- Caucasian
Exclusion Criteria:
- Chronic diseases
- Medication use
- Smoking
- Excessive alcohol consumption
- Seasonal allergies
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
PLACEBO_COMPARATOR: Placebo
6 weeks high-intensity interval training + placebo intake
|
Placebo: Lactose capsules
6 weeks HIIT
|
EXPERIMENTAL: Blockade
6 weeks high-intensity interval training + histamine H1/H2 receptor blockade
|
6 weeks HIIT
H1 receptor antagonist: 540 mg Fexofenadine Hydrochloride
H2 receptor antagonist: 40 mg Famotidine
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in cardiorespiratory fitness
Time Frame: Before, after 3 weeks and after 6 weeks of exercise training
|
Change in maximal oxygen uptake during incremental cycling test on cycle ergometer during the 6 week training period
|
Before, after 3 weeks and after 6 weeks of exercise training
|
Change in peak aerobic power output
Time Frame: Before, after 3 weeks and after 6 weeks of exercise training
|
Change in peak power output during incremental cycling test on cycle ergometer during the 6 week training period
|
Before, after 3 weeks and after 6 weeks of exercise training
|
Change in whole-body insulin sensitivity
Time Frame: Before and after 6 weeks of exercise training
|
Change from baseline in Matsuda index for whole-body insulin sensitivity derived from Oral Glucose Tolerance Test after the 6 week training period
|
Before and after 6 weeks of exercise training
|
Change in microvascular function
Time Frame: Before and after 6 weeks of exercise training
|
Change from baseline in microvascular function (Single Passive Leg Movement technique) after the 6 week training period
|
Before and after 6 weeks of exercise training
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in skeletal muscle capillarization
Time Frame: Before and after 6 weeks of exercise training
|
Change from baseline in skeletal muscle capillarization (immunohistochemistry) after the 6 week training period
|
Before and after 6 weeks of exercise training
|
Change in skeletal muscle enzyme activity
Time Frame: Before and after 6 weeks of exercise training
|
Change from baseline in enzyme activity assessment of markers of relevance for skeletal muscle function after the 6 week training period
|
Before and after 6 weeks of exercise training
|
Change in skeletal muscle protein content
Time Frame: Before and after 6 weeks of exercise training
|
Change from baseline in Western Blot assessment of markers of relevance for skeletal muscle function after the 6 week training period
|
Before and after 6 weeks of exercise training
|
Change in power output at Gas Exchange Threshold (GET)
Time Frame: Before, after 3 weeks and after 6 weeks of exercise training
|
Change from baseline in GET during incremental cycling test after the 6 week training period
|
Before, after 3 weeks and after 6 weeks of exercise training
|
Change in power output at Respiratory Compensation Point (RCP)
Time Frame: Before, after 3 weeks and after 6 weeks of exercise training
|
Change from baseline in RCP during incremental cycling test after the 6 week training period
|
Before, after 3 weeks and after 6 weeks of exercise training
|
Change in time to exhaustion performance test
Time Frame: Before, after 3 weeks and after 6 weeks of exercise training
|
Change in time to exhaustion test (performed after incremental cycling test) during the 6 week training period
|
Before, after 3 weeks and after 6 weeks of exercise training
|
Change in heart rate during submaximal cycling
Time Frame: Before and after 6 weeks of exercise training
|
Change from baseline in heart rate during submaximal cycling after the 6 week training period
|
Before and after 6 weeks of exercise training
|
Change in substrate oxidation during submaximal cycling
Time Frame: Before and after 6 weeks of exercise training
|
Change from baseline in substrate oxidation during submaximal cycling test (estimated via gas exchange data) after the 6 week training period
|
Before and after 6 weeks of exercise training
|
Change in blood lactate accumulation during submaximal cycling
Time Frame: Before and after 6 weeks of exercise training
|
Change from baseline in capillary lactate concentration at end of submaximal cycling test after the 6 week training period
|
Before and after 6 weeks of exercise training
|
Change in cycling efficiency during submaximal cycling
Time Frame: Before and after 6 weeks of exercise training
|
Change from baseline in cycling efficiency (estimated via gas exchange data) after the 6 week training period
|
Before and after 6 weeks of exercise training
|
Change in fasted serum insulin concentrations
Time Frame: Before and after 6 weeks of exercise training
|
Change from baseline in fasted blood concentrations of insulin after the 6 week training period
|
Before and after 6 weeks of exercise training
|
Change in fasted serum glucose concentrations
Time Frame: Before and after 6 weeks of exercise training
|
Change from baseline in fasted blood concentrations of glucose after the 6 week training period
|
Before and after 6 weeks of exercise training
|
Change in fasted serum cholesterol concentrations
Time Frame: Before and after 6 weeks of exercise training
|
Change from baseline in fasted blood concentrations of cholesterol after the 6 week training period
|
Before and after 6 weeks of exercise training
|
Change in fasted serum triglyceride concentrations
Time Frame: Before and after 6 weeks of exercise training
|
Change from baseline in fasted blood concentrations of triglyceride after the 6 week training period
|
Before and after 6 weeks of exercise training
|
Change in resting blood pressure
Time Frame: Before and after 6 weeks of exercise training
|
Change from baseline in resting mean arterial blood pressure after the 6 week training period
|
Before and after 6 weeks of exercise training
|
Change in resting heart rate
Time Frame: Before and after 6 weeks of exercise training
|
Change from baseline in resting heart rate after the 6 week training period
|
Before and after 6 weeks of exercise training
|
Change in body weight
Time Frame: Before and after 6 weeks of exercise training
|
Change from baseline in total body weight after the 6 week training period
|
Before and after 6 weeks of exercise training
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
October 2, 2019
Primary Completion (ACTUAL)
December 18, 2019
Study Completion (ACTUAL)
April 14, 2021
Study Registration Dates
First Submitted
June 9, 2020
First Submitted That Met QC Criteria
June 25, 2020
First Posted (ACTUAL)
June 29, 2020
Study Record Updates
Last Update Posted (ACTUAL)
July 30, 2021
Last Update Submitted That Met QC Criteria
July 29, 2021
Last Verified
July 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Gastrointestinal Agents
- Anti-Ulcer Agents
- Anti-Allergic Agents
- Histamine H1 Antagonists
- Histamine Antagonists
- Histamine Agents
- Histamine H1 Antagonists, Non-Sedating
- Histamine H2 Antagonists
- Famotidine
- Fexofenadine
Other Study ID Numbers
- HIST-TRAINING
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Physical Activity
-
Istinye UniversityCompletedPhysical Activity | Youth | Physical Activity Barriers | Physical Activity FacilitatorsTurkey
-
Istanbul Kültür UniversityWithdrawnPhysical Activity Level | Physical Activity Awareness
-
Georgetown UniversityUniversity of PennsylvaniaCompletedPhysical Activity | Motor ActivityUnited States
-
Assistance Publique - Hôpitaux de ParisTerminatedPhysical Activity | Physical DisabilityFrance
-
University of Colorado, DenverCompletedPhysical Activity | Physical ImpairmentUnited States
-
PXL University CollegeHasselt UniversityNot yet recruitingPhysical Activity - Digital Phenotyping - Activity Tracking
-
University of ExtremaduraThe Spanish Ministry of Science, Innovation and UniversitiesRecruitingPhysical Activity | Cognition | Physical Fitness | AdolescentsSpain
-
AdventHealth Translational Research InstituteWake Forest UniversityRecruiting
-
Wake Forest University Health SciencesMayo Clinic; National Institute of Diabetes and Digestive and Kidney Diseases... and other collaboratorsRecruitingPhysical ActivityUnited States
-
Wake Forest University Health SciencesMayo Clinic; National Institute of Diabetes and Digestive and Kidney Diseases... and other collaboratorsRecruiting
Clinical Trials on Lactose
-
Mashhad University of Medical SciencesCompletedNausea | VomitingIran, Islamic Republic of
-
Evolve BioSystems, Inc.TerminatedInfantile ColicUnited States
-
Kantonsspital AarauTerminatedUrinary Tract InfectionsSwitzerland
-
Children's University Hospital, IrelandUniversity College Dublin; Health Research Board, Ireland; Medical Research Charities...Completed
-
Ansun Biopharma, Inc.National Institute of Allergy and Infectious Diseases (NIAID)Completed
-
University of Illinois at Urbana-ChampaignCompletedCognitive Change | Physiological Stress | Gastrointestinal HealthUnited States
-
University of BathUniversity of Oxford; British Heart FoundationRecruiting
-
University Hospitals, LeicesterCompletedUlcerative Colitis | Lactose IntoleranceUnited Kingdom
-
Boston Scientific CorporationWithdrawnMigraineDenmark, Norway, United Kingdom
-
American University of Beirut Medical CenterTerminatedAcute GastroenteritisLebanon